Peptilogics
Karen Corbett is a Computational Scientist specializing in Biophysics and Biochemistry at Peptilogics since November 2021. Previously, Karen served as a Postdoctoral Research Assistant at RMIT University from October 2021 to October 2022, focusing on potassium ion channels and studying their mechanism and structure-function relationships. At Monash University, as a Postdoctoral Researcher from September 2019 to June 2021, Karen employed temperature replica exchange molecular dynamics to explore the conformation and permeability of cyclic peptides, resulting in significant publications and a funded research proposal. Karen's earlier work includes research and teaching roles at Florida State University and James Madison University, supported by a PhD in Molecular Biophysics from Florida State University.
This person is not in any offices
Peptilogics
Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics' lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.